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Primary fallopian tube carcinomas (PFTCs) are rarely encoun-
tered gynecological neoplasms and account for 0.3e1% of female
genital tract malignancies [1,2]. PFTCs most commonly occur in
patients aged 40e65 years, with a median age of 55 years. Difﬁ-
culties are encountered in the clinical and pathological diagnosis of
PFTCs because they share the same clinical ﬁndings and patho-
logical features as serous epithelial ovarian cancer and primary
peritoneal serous carcinoma [1].
Similar to ovarian cancer, PFTC can spread by transcoelomic
exfoliation of cancer cells in the abdominal cavity, which causes
peritoneal carcinosis. Direct spread, transluminal migration,
lymphatic and hematogenous metastasis have also been shown [2].
Distant metastases are more frequently seen in PFTC than in
ovarian cancer [3].
PFTC is usually asymptomatic. The most common symptom is
abdominal pain, which can be colicky due to tubal peristaltism, or
blunt as a result of tubal distention. Patients are usually diagnosed
at an advanced stage, accompanied by widespread pelvic metas-
tasis due to nonspeciﬁc clinical signs and symptoms [4].
Isolated supraclavicular lymph node metastasis is a rare mani-
festation of tubal carcinoma. In the literature, only three patients
[5e7] who presented with isolated supraclavicular lymph node
were diagnosed as having PFTC. In this research letter, we aimed to
discuss the diagnosis and follow-up of a patient whowas diagnosed
with PFTC with isolated supraclavicular lymph node metastasis.* Corresponding author. Department of Obstetrics and Gynecology, Zeynep Kamil
Education and Research Hospital, Operator Doctor Burhanettin Üstünel Caddesi No:
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).A woman aged 60 years (gravida 7, parity 5) who had been
postmenopausal for 12 years, was admitted to the general surgery
department with a palpable left supraclavicular lymph node. An
excisional biopsy of the supraclavicular lymph node was per-
formed. Pathological examination of the biopsy material revealed
papillary adenocarcinoma metastasis (Figure 1A). Immunohisto-
chemical staining was performed to determine the origin of the
primary tumor. The results showed diffuse-strong nuclear WT-1
and p53, cytoplasmic cytokeratin 7, focal-strong nuclear proges-
terone receptor, and sporadic nuclear estrogen receptor staining.
cytokeratin 20, thyroid transcription factor-1 and thyroglobulin
staining were not detected. According to the ﬁnal pathology report,
breast or ovarian tumors were preliminarily diagnosed according to
the morphological and immunohistochemical results. The patient
was re-evaluated in the general surgery department. Breast ex-
amination, mammography and breast ultrasound were performed
to conﬁrm absence of breast tumor. Both gastroscopy and colo-
noscopy revealed normal results. The patient was referred to our
department for evaluation of gynecological oncology.
In the gynecological examination, there was no abnormal
vaginal discharge or palpable mass in the pelvic palpation. No
pathological ﬁndingwas observed by transvaginal ultrasonography.
The cervicovaginal smear and endometrial sampling were normal.
The patient had only mild pelvic and back pain. Her family history
was unremarkable. Serum carbohydrate antigen (CA)-125 level was
901 U/mL.
There were lymph nodes with pathological size and enhance-
ment localized at L4-5 lumbar spine in thoracoabdominal
computed tomography (CT). No other abnormality was found. The
patient underwent positron emission tomography combined with
CT (PET-CT). PET-CT revealed an intense 28 mm  19 mm hyper-
metabolic area in the posterior soft tissue and a hypodense nodular
lesion located in the left adnexal area. Multiple retroperitoneal
lymphadenopathies were also detected in the right retrocaval area
(Figure 1B).
The patient was diagnosed with advanced-stage ovarian tumor
and underwent surgery in July 2011. The patient had a totalby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Figure 1. (A) Serous carcinoma metastasis of the fallopian tube in supraclavicular lymph node (hematoxylin and eosin, 100). (B) Appearance of the tumor in positron emission
tomography/computed tomography. (C) Serous carcinoma arising from the left fallopian tube lumen (hematoxylin and eosin, 40). (D) Appearance of the recurrence site in
magnetic resonance imaging.
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appendectomy, total omentectomy, and pelvic para-aortic lym-
phadenectomy (8 left pelvic lymph nodes, 12 right pelvic- and 12
para-aotric lymph nodes). No intraoperative macroscopic tumoral
implant or ascites was observed. The right tuba and the omentum
were normal. A lobulated-contoured lesion located in the ampulla
of left fallopian tube was seen. A surgical specimen was sent for
frozen section examination, which revealed a 2.5-cm diameter
malignant tumor in the ampulla of the left fallopian tube. The
diagnosis was tubal high-grade papillary serous adenocarcinoma in
the ﬁnal pathology report (Figure 1C).
We observed tumoral invasion of the muscular layer and
serosa of the fallopian tube, but extension beyond the serosa was
not observed. Also, serous tubal intraepithelial adenocarcinoma
(STIC) was found in the right fallopian tube. There was no tu-
moral implant in the pelvic, para-aortic lymph nodes, omentum,
or appendix. As a result of these evaluations, the patient was
diagnosed with PFTC with isolated supraclavicular lymph node
metastasis.
She underwent six cycles of combined paclitaxel and carbo-
platin chemotherapy after the primary surgery. Postoperative
recurrence was monitored using serum CA-125 levels. Whenelevated serum CA-125 level (182 U/mL) was detected, the results
of magnetic resonance imaging showed a solid mass of approxi-
mately 36 mm  26 mm in the left para-aortic area, inferior to the
renal artery (Figure 1D). Total disease-free survival was 42 months.
Themass was considered as recurrent disease; therefore, secondary
cytoreductive surgery and adjuvant chemotherapy was planned.
Advanced epithelial ovarian cancer will ultimately develop
recurrent disease. However, the standard treatment of womenwith
recurrent ovarian cancer remains poorly deﬁned. Surgery for
recurrent ovarian cancer is suggested to be associated with
increased overall survival.
The theoretical beneﬁt from cytoreductive surgery relates to
removing large tumor volumes that have a decreased growth
fraction and poor blood supply, thereby improving the efﬁcacy of
chemotherapeutic agents.
Primary fallopian tube carcinomas are rarely encountered ma-
lignancies and there is little information on their etiology and
treatment. Some data suggest that chronic tubal inﬂammation,
infertility, tuberculosis salpingitis, and tubal endometriosis play a
role in the etiology of PFCT [8].
Histopathologically, the presence of p53 in the fallopian tube
epithelium indicates proliferative lesions named serous tubal
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cause STIC [10]. STIC might be a precursor of fallopian tube, ovarian
and peritoneal high-grade serous carcinoma [10]. In our case,
although high-grade serous carcinoma was found in the left fallo-
pian tube, STIC was present in the right fallopian tube.
Lymphatic discharge of the fallopian tubesmay differ according to
the affected portion of the fallopian tube. Anatomically, lymphatic
drainage of fallopian tube to the pelvic lymph nodes occurs through
the lymphatic channels located in the proximal part of the uterus, and
para-aortic lymph node drainage occurs through the lymphatic
channels located indistal tube andﬁmbria [11]. Sometimes, lymphatic
drainage of the medial part occurs through the round ligament lym-
phatics to the inguinal region [12]. Bothpositive para-aortic andpelvic
lymph node involvement is seen 42e59% of patients [2].
Similar to the surgical treatment of epithelial ovarian cancer, the
aim in the treatment of PFTC is complete removal of the tumor [13].
The standard surgical treatment is total abdominal hysterectomy,
bilateral salpingo-oophorectomy, appendectomy, infracolic omen-
tectomy, pelvic- and para-aortic lymph node dissection, and
abdominal washing and peritoneal sampling [14].
International Federation of Gynecology and Obstetrics (FIGO)
staging is the most coherent prognostic factor related to survival
[15]. For patients at an advanced stage, it is necessary to remove as
much tumor mass as possible and perform aggressive cytoreduc-
tive surgery [16]. Although widespread intra-abdominal tumoral
implant was not observed in this patient, the presence of supra-
clavicular lymph node metastases was evaluated as Stage 4 disease,
and the most extensive surgical resection was performed to
maximize survival. Supraclavicular lymph node metastasis without
widespread intra-abdominal disease is a rare event. In the litera-
ture, metastases were reported in only three patients who pre-
sented with isolated supraclavicular lymph nodes. Piura et al [5]
reported the ﬁrst in 1989; their patient presented with isolated
supraclavicular metastasis and was diagnosed as having fallopian
tube carcinoma. The second was a woman aged 70 years reported
by Scholz et al [6]. Their patient was diagnosed with a left supra-
clavicular mass with PFTC at Stage IV. The patient was successfully
treated with carboplatin after surgery. Sakurai et al [7] reported a
patient aged 76 years who presented with a supraclavicular lymph
node. Biopsy of the lesion revealed metastatic adenocarcinoma and
the primary lesion originated from the right fallopian tube. Two
years of disease-free survival was reported. Our patient was elderly,
similar to the patients in the literature, and had no gynecological
symptoms.
CA-125 is the most widely used tumor marker in the diagnosis
and follow-up of PFTC. Elevated pretreatment levels were reported
in 80% of patients with PFTC [17]. In our case, the CA-125 level was
increased; there was an isolated supraclavicular metastasis, and no
intra-abdominal disease. Also, recurrence after 42 months was
determined by an increase in serum CA-125 levels.
Secondary cytoreductive surgery is deﬁned as the removal of
recurrent masses after remission. The aim of cytoreductive surgery
is to extend survival; it is not a curative treatment. The obvious
beneﬁts of optimal primary surgery in advanced-stage ovarian
cancer have led researchers to investigate secondary cytoreductive
surgery for recurrent disease after clinical remission. Additionally,
various chemotherapeutic agents containing platinum have been
administered to patients after secondary cytoreductive surgery
[18].
A meta-analysis published in 2009 revealed that complete cyto-
reductive surgery independently increasedoverall survival inpatients
with recurrent ovarian cancer [19]. A prospective study by Eisenkop
et al [20] reported 87% decreased mortality after secondary cytore-
ductive surgery in disease-free patients as compared with patients
with residual disease. The median survival rate was reported as44.4 months in the complete secondary cytoreduction group,
whereas it was 19.3 months in the suboptimal cytoreduction group.
Our patient's disease-free survival time after primary surgery
was 42 months. Platinum-based chemotherapy following second-
ary cytoreductive surgery was planned due to recurrence.
PFTC should be considered as a systemic disease because it may
be accompanied with distant lymph node metastases without
widespread pelvic disease; its treatment and follow-up should be
scheduled accordingly. Furthermore, we believe that it is appro-
priate to use CA-125 in the diagnosis and follow-up of patients with
isolated supraclavicular lymph node metastasis; however, if me-
tastases originate from other primary origins, such as lung and
breast, CA-125 may not be a good marker.Conﬂicts of interest
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